Inflammatory bowel disease
About this PSP
Inflammatory Bowel Disease (IBD) affects a wide range of people and is a major burden on the health and wealth of the nation.
This PSP was set up by the
- British Society of Gastroenterology
- Crohn’s and Colitis UK
- Royal College of Nursing
- Association of Coloproctology of Great Britain and Ireland
- British Dietetic Association
- British Society Of Paediatric Gastroenterology, Hepatology and Nutrition
- Crohn’s in Childhood Research Association
- Core (now GUTS UK)
- The Primary Care Society for Gastroenterology
with input from the National Institute for Health and Care Research (NIHR) Gastroenterology Specialty Group and NIHR Children Specialty Group.
In the first survey, a total of 1,671 uncertainties from 531 participants were collected.
See news from this PSP: June 2019
The IBD PSP Top 10 was published in February 2015.
Key documents
Top 10 priorities
The most important questions
- What is the optimal treatment strategy considering efficacy, safety and cost-effectiveness (immunomodulators, biologics, surgery, combinations) in IBD management: selecting the right patient group, right stage of disease, and assessing potential for withdrawal?
- What are the optimal markers/ combinations of markers (clinical, endoscopic, imaging, genetics, other biomarkers) for stratification of patients with regards to a) disease course and b) monitoring disease activity and c) treatment response?
- What role does diet have in the management of mildly active or inactive ulcerative colitis or Crohn’s Disease to achieve normal daily activities and symptom control?
- How can pain be most effectively managed in people with IBD?
- What is an optimal treatment strategy for perianal Crohn’s Disease and what individual factors determine this?
- What is the best treatment for controlling diarrhoea and/or incontinence symptoms in people with IBD, including novel pharmacological and non-pharmacological options? Is high-dose Loperamide safe and effective in the treatment of diarrhoea in IBD?
- What is the optimal dietary therapy (liquid enteral diet and/or reintroduction diet) and duration to achieve mucosal healing in active IBD and/or remission either as a primary or adjunctive treatment? Is there a difference between adults and children?
- What is the association between IBD and fatigue and how should it be managed?
- Does early surgery or later surgery for terminal ileal Crohn’s disease result in better outcomes (quality of life, cost-effectiveness)?
- Does influencing the gut microbiota influence the course of IBD?